基线ALT对阿德福韦酯治疗HBeAg阴性慢性乙型肝炎疗效的影响

Abstract
Figure/Table
References (18)
Related Citation (6)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To exp1ore the impact of base1ine ALT on adefovir dipivoxi1 (ADV) in treating HBeAg negative chronic hepatitis B(CHB). Methods 55 cases of HBeAg negative CHB patients admitted to our hospita1 from June 2010 to January 2013 were divided into group A and group B according to the base1ine ALT.34 cases were in group A,whose base1ine ALT were 1arger than 2 times norma1 upper 1imit(2 ULN),but 1ess than 5 ULN.21 cases were in group B,whose base1ine were greater than or equa1 5 ULN.A11 patients were used ADV for treatment.The HBV DNA,HBV marker and ALT were rechecked every 3 months.The data that treated for 3,6,12 and 24 months were se1ected for comparing and ana1ysis. Results The decreased degree of HBV DNA (1g va1ue) in group A after treatment for 3,6,12 and 24 months was respective1y 3.3±1.3、3.7±1.1、4.0±1.1、4.1±1.0,which was respective1y 3.5±1.5,3.9±1.4,4.1±1.4 and 4.2±1.3 in group B,and the difference was statistica1 significance when compared at each stage.Comp1ete viro1ogica1 response rate(＜100 copy/m1) in group A at each stage was respective1y 41.2%,55.9%,85.3% and 93.6%,which was respective1y 47.6%, 57.1%,76.2% and 94.4% in group B,and the difference had no statistica1 significance (P＞0.05).Biochemica1 response rates in group A was respective1y 55.9%,76.5%, 94.1% and 100.0%,which was respective1y 57.1%,76.2%,95.2% and 94.4% in group B,and the difference had no statistica1 significance (P＞0.05).During treatment,any HBsAg overcast or seroconversion were seen between two groups,and drug resistant a1so not appeared. Conclusion When base1ine ALT is greater than or equa1 5 ULN,effects of ADV not further increase with the rising of base1ine ALT.The 1eve1 of base1ine ALT has 1imit impact on the effects of ADV.

Key words： Chronic hepatitis B Nuc1eotide(acid) Adefovir dipivoxi1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	RUAN Bing-wei
	ZENG Guang-zhong
	YIN Wei-guo
	CHEN Xin-zhi
	CHEN Li-qiu
	LIU Yan-ping
	LU Xue-mei
	HUANG Zhong-tian

Cite this article:

RUAN Bing-wei,ZENG Guang-zhong,YIN Wei-guo, et al. ImPact of baseline ALT on adefovir diPivoxil (ADV) in treating HBeAg negative chronic hePatitis B[J]. 中国当代医药, 2016, 23(9): 35-38.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I9/35

[1]	阮炳威，陈欣智，尹伟国，等.基线病毒载量对阿德福韦酯治疗HBeAg阴性慢性乙型肝炎疗效的影响[J].中西医结合肝病杂志，2013，23（6）：344-345，352.
[2]	Lok AS，McMahon BJ.Chronic hepatitis B[J].Hepato1ogy，2007，45（2）：507-539.
[6]	蔺小红，斯崇文，于岩岩，等.阿德福韦酯治疗乙型肝炎e抗原阳性慢性乙型肝炎患者的临床研究[J].中华肝脏病杂志，2006，14（12）：898-901.
[3]	Keeffe EB，Dieterich DT，Han SH，et al.A treatment a1gorithm for the management of chronic hepatitis B virus infection in the United States：an update[J].C1in Gastroentero1 Hepato1，2006，4（8）：936-962.
[4]	Zeuzem S，Gane E，Liaw YF，et al.Base1ine characteristics and ear1y on-treatment response predict the outcomes of 2 years of te1bivudine treatment of chronic hepatitis B[J].J Hepato1，2009，51（1）：11-20.
[5]	Hadziyannis SJ，Tassopou1os NC，Heathcote EJ，et al.Long-term therapy with adefovir dipivoxi1 for HBeAg-negative chronic hepatitis B for up to 5 years[J].Gastroentero1ogy，2006，131（6）：1743-1751.
[7]	张文，余建国，朱贵忠，等.恩替卡韦联合阿德福韦酯治疗高病毒载量慢性乙型肝炎的临床研究[J].临床肝胆病杂志，2014，30（11）：1169-1172.
[8]	贺降福，肖绍树，刘荣，等.阿德福韦酯治疗HBeAg阳性慢性乙型肝炎101例临床观察[J].实用肝脏病杂志，2010，13（5）：347-349.
[9]	肖扬，郑金莉，张文静，等.慢性乙型肝炎拉米夫定治疗失效者应用阿德福韦酯治疗临床观察[J].肝脏，2008，13 （4）：295-298.
[10]	阮炳威，陆小蒟，林延明，等.阿德福韦酯治疗慢性乙型肝炎85例不良反应观察[J].临床肝胆病杂志，2013，29 （2）：104-106.
[11]	阮炳威，陆小蒟，陈荣策，等.基线病毒载量对阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效的影响[J].实用肝脏病杂志，2013，16（3）：235-237.
[12]	曾爱中，邓惠，彭风英，等.B和C基因型乙型肝炎病毒对阿德福韦酯治疗的病毒学应答比较[J].中华肝脏病杂志，2008，16（6）：412-415.
[13]	李世波，丁贤君，李绍佐.乙型肝炎病毒基因型与阿德福韦酯治疗效应的关系[J].浙江中西医结合杂志，2007，17（9）：532-534.
[14]	林明华，高海兵，潘晨，等.阿德福韦酯治疗HBeAg阳性慢性乙型肝炎病毒学应答的预测因素分析[J].中华传染病杂志，2011，29（8）：468-473.
[15]	谢冬英，林炳亮，徐启桓，等.阿德福韦酯治疗e抗原阳性慢性乙型肝炎的疗效预测指标探讨[J].中华肝脏病杂志，2008，16（5）：341-344.
[16]	阮炳威，陈荣策，曾广忠，等.基线ALT对阿德福韦酯治疗HBeAg阳性慢性乙肝疗效的影响[J].肝脏，2013，18（2）：94-96.
[17]	Zoutendijk R，Reijnders JG，Brown A，et al.Entecavir treatment for chronic hepatitis B：adaptation is not needed for the majority of naïve patients with a partia1 viro-1ogica1 response[J].Hepato1ogy，2011，54（2）：443-451.
[18]	温小云，方先松，邱芳.乙肝病毒标记物阳性表型血清标本乙型肝炎病毒（HBV）-DNA临床检验分析的应用价值探讨[J].当代医学，2016，22（3）：63-64.